Clinuvel Pharmaceuticals company info

What does Clinuvel Pharmaceuticals do?
Clinuvel Pharmaceuticals (ASX:CUV) is an Australian biopharmaceutical company that develops and commercialises novel phototherapeutic drugs to treat and protect people with genetic photosensitivity disorders. The company's flagship product, Scenesse®, is a prescription drug for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder that causes severe pain and burning sensations in the skin when exposed to sunlight.
Clinuvel Pharmaceuticals company media
Company Snapshot

Is Clinuvel Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Clinuvel Pharmaceuticals employ?

people
Employees
64

What sector is Clinuvel Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Clinuvel Pharmaceuticals?

location pin
Head Office
Victoria, Australia

What year was Clinuvel Pharmaceuticals founded?

founded flag
Year Founded
1987
What does Clinuvel Pharmaceuticals specialise in?
/Biotech /Healthcare /Medical /Pharmaceuticals /Manufacturing /Drugs

What are the products and/or services of Clinuvel Pharmaceuticals?

Overview of Clinuvel Pharmaceuticals offerings
Development of novel photoprotective drugs: Clinuvel Pharmaceuticals is a specialty pharmaceutical company focused on developing novel photoprotective drugs for the prevention and treatment of light-related skin disorders.
Commercialization of Scenesse: Scenesse is Clinuvel Pharmaceuticals' flagship product, a prescription oral medication that helps to protect patients with genetic photosensitivity disorders from the harmful effects of ultraviolet (UV) radiation.
Research and development of new drugs and treatments: Clinuvel Pharmaceuticals is actively researching and developing new drugs and treatments for a range of light-related skin disorders, including actinic keratosis, basal cell carcinoma, and squamous cell carcinoma.
Clinical trials of new drugs and treatments: Clinuvel Pharmaceuticals is conducting a number of clinical trials of new drugs and treatments for light-related skin disorders.
Manufacturing and distribution of Scenesse: Clinuvel Pharmaceuticals manufactures and distributes Scenesse to patients around the world.

Who is in the executive team of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals leadership team
  • Dr. Philippe Jacques Wolgen M.B.A., M.D.
    Dr. Philippe Jacques Wolgen M.B.A., M.D.
    CEO, MD & Director
  • Mr. Darren Michael Keamy B.Com., CPA
    Mr. Darren Michael Keamy B.Com., CPA
    CFO & Company Secretary
  • Dr. Dennis J. Wright
    Dr. Dennis J. Wright
    Chief Scientific Officer
  • Mr. Lachlan  Hay
    Mr. Lachlan Hay
    Director of Global Operations
  • Mr. Malcolm  Bull
    Mr. Malcolm Bull
    Head of Australian Operations & Investor Relations
  • Dr. Rose  Quadbeck-Diel
    Dr. Rose Quadbeck-Diel
    Senior Vice President of Regulatory Affairs
  • Dr. Azza  Hamila
    Dr. Azza Hamila
    Head of Quality & Drug Safety